Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.

European urology·2026
Same author

EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.

European urology·2026
Same author

Development and Validation of a Computational Histology Artificial Intelligence-Powered Biomarker in Metastatic Hormone-Sensitive Prostate Cancer on Randomized Phase III Trials.

JCO precision oncology·2026
Same author

Venous thromboembolism after penile cancer surgery: a UK PeCaN study.

BJU international·2026
Same author

Overall Survival Benefit from Metformin in High-volume Metastatic Hormone-sensitive Prostate Cancer in STAMPEDE Signals an Opportunity for Metabolically-targeted Therapies in Prostate Cancer.

European urology oncology·2026
Same author

AI-Based Pathology classifier Predicts Sensitivity to Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer: A Biomarker Analysis of the ENZAMET Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

相关实验视频

Updated: Sep 10, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K

瘤全转录组表达分类器预测晚期前列腺癌的治疗敏感性

Emily Grist1, Peter Dutey-Magni2, Marina A Parry1

  • 1Cancer Institute, University College London, London, UK.

Cell
|August 27, 2025
PubMed
概括

新的生物标志物可以预测前列腺癌的存活率和对多西等治疗的反应. 这些发现可以为晚期前列腺癌患者提供个性化药物,改善治疗选择和结果.

关键词:
时间在STAMPEDE试验中亚比拉其他药物前列腺癌全转录组表达式分类器

更多相关视频

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

相关实验视频

Last Updated: Sep 10, 2025

miRNA Expression Analyses in Prostate Cancer Clinical Tissues
11:29

miRNA Expression Analyses in Prostate Cancer Clinical Tissues

Published on: September 8, 2015

10.9K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.9K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

科学领域:

  • 癌症学
  • 基因组学
  • 翻译研究

背景情况:

  • 晚期前列腺癌的治疗依赖于荷尔蒙疗法,
  • 目前没有预测性测试可指导患者选择最佳治疗方法.

研究的目的:

  • 为了确定晚期前列腺癌的新生物标志物治疗配对.
  • 在3期试验中的患者中研究生物途径与生存结果之间的关联.

主要方法:

  • 在1523个前列腺瘤中分析了全转录组表达特征和免疫组织化学标记 (Ki-67,PTEN).
  • 在3期多塞或阿比拉试验中的患者中,研究生物标志物与14年生存率之间的关联.

主要成果:

  • 雄激素受体信号与更长的存活时间相关,而增加的增殖预测了更短的存活时间.
  • 在转移性前列腺癌中,解读RNA信号预测了dcetaxel的生存益处.
  • 基于转录基因的PTEN失活分类确定了在激素治疗中存活时间较短但对多塞塔克塞尔敏感的瘤.

结论:

  • 转录组分类器可以预测在晚期前列腺癌中使用多塞塔克塞尔的益处.
  • 基于生物标志物的治疗选择可以改善患者的治疗和治疗结果.